RemedyRePack Cefixime Capsules Recall: Failed Impurities Risk
RemedyRePack recalls Cefixime 400mg capsules with failed impurities/degradation specs. Rx-only products from specific lots and NDCs may pose safety risks.
Recall notice
Failed Impurities/Degradation Specifications
Contact the company
What happened, in plain English
RemedyRePack is recalling certain Cefixime 400 mg capsules due to failed impurities or degradation specifications. This could potentially lead to unsafe drug content in the medication. Read more at govinfonow.com/recall/35412-remedyrepack-cefixime-capsules-recall-failed-impurities-risk.
Source Summary by GovInfoNow · govinfonow.com/recall/35412-remedyrepack-cefixime-capsules-recall-failed-impurities-risk · Updated August 17, 2026 · FDA enforcement record: FDA #D-0360-2022
Cite this page
“RemedyRePack Cefixime Capsules Recall: Failed Impurities Risk.” GovInfoNow, updated August 17, 2026. https://govinfonow.com/recall/35412-remedyrepack-cefixime-capsules-recall-failed-impurities-risk. Based on FDA recall #D-0360-2022 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0360-2022%22&limit=1).
Why it’s dangerous
The capsules may contain impurities or have degraded beyond safe levels, which could affect the medication's safety and effectiveness. This issue occurs in specific batches with particular lot numbers and expiration dates.
Who’s affected
Prescription holders of the specific Cefixime 400 mg capsules with the listed NDC numbers and lot codes are affected. Patients taking these medications should be cautious.
How to tell if you have this one
Check for the product name 'Cefixime 400 mg capsule' with NDC numbers 70518-2749-02 or 70518-2749-03. Look for specific lot numbers and expiration dates listed in the recall notice.
- Brand
RemedyRePack- Category
Drug
What to do — step by step
Check Product Details
Verify your capsule's NDC number and lot code against the list provided in the recall notice.
Where it went and when
Where it was distributed
Distributed in Michigan and Pennsylvania.
FDA distribution: “Product was distributed to two direct accounts in MI and PA.” States read from FDA’s own wording; “not listed” means the notice does not name it.
States: Michigan, Pennsylvania.
Recall timeline
FDA terminated this recall 3 months after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0360-2022 (December 29, 2021) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0360-2022 to see it in context.
- Plain-language summary written by qwen3:4b on August 17, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.